![Sandeep Laumas](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Sandeep Laumas
Finanzdirektor/CFO bei
INSTIL BIO, INC.
Vermögen: 1 Mio $ am 30.06.2026
Profil
Sandeep Laumas is the founder of Bearing Circle Capital LP, founded in 2007, serving as Managing Director.
Current jobs include Director at Globavir Biosciences, Inc. since 2015; Independent Director at BioXcel Therapeutics, Inc. since 2017; Independent Director at Unicycive Therapeutics, Inc. since 2018; and Chief Financial & Business Officer at Instil Bio, Inc. since 2021.
Former jobs include Managing Director at North Sound Capital LLC (Old) from 2003 to 2008; Director at Parkway Holdings Ltd. in 2010; Director at Agilus Diagnostics Ltd. from 2011 to 2012; Director at BioXcel Corp.
from 2013 to 2017; Director at 9 Meters Biopharma, Inc. from 2020 to 2021; Director at Invea Therapeutics, Inc.; and Analyst at Balyasny Asset Management LP from 2001 to 2003.
Education includes an undergraduate degree from Cornell University in 1990 and a doctorate from Albany Medical College in 1995.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
INSTIL BIO, INC. 2,36 % | 13.04.2026 | 159 999 ( 2,36 % ) | 1 Mio $ | 30.06.2026 |
| 14.05.2026 | 10 583 ( 0,04 % ) | 49 634 $ | 30.06.2026 | |
| 09.01.2026 | 0 ( -.--% ) | - $ | 30.06.2026 |
Aktive Positionen von Sandeep Laumas
| Unternehmen | Position | Beginn |
|---|---|---|
| BIOXCEL THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.09.2017 |
| UNICYCIVE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 01.01.2018 |
| INSTIL BIO, INC. | Finanzdirektor/CFO | 01.02.2021 |
Bearing Circle Capital LP | Gründer | 01.08.2007 |
Globavir Biosciences, Inc.
 Globavir Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in development of therapeutics and diagnostics for treatment of infectious diseases | Direktor/Vorstandsmitglied | 01.01.2015 |
Ehemalige bekannte Positionen von Sandeep Laumas
| Unternehmen | Position | Ende |
|---|---|---|
Invea Therapeutics, Inc.
 Invea Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or IMIDs | Direktor/Vorstandsmitglied | 01.04.2022 |
| 9 METERS BIOPHARMA, INC. | Vorstandsvorsitzender | 30.04.2020 |
BioXcel Corp.
 BioXcel Corp. Data Processing ServicesTechnology Services Provides pharma data analytics solutions | Direktor/Vorstandsmitglied | 01.08.2017 |
Agilus Diagnostics Ltd.
 Agilus Diagnostics Ltd. Medical/Nursing ServicesHealth Services Provides diagnostic services | Direktor/Vorstandsmitglied | 01.01.2012 |
| ░░░░░░░ ░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Sandeep Laumas
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
90
Beziehungen ersten Grades
14
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 14 |
|---|---|
North Sound Capital LLC (Old)
 North Sound Capital LLC (Old) Investment ManagersFinance NSC is a multi-cap value hedge fund manager that primarily shorts US stocks without sector restriction. Their research effort is fundamental and makes use of in-house and Wall Street research. Sector weighting is typically tied to the Barra S&P 500 index. | Finance |
Balyasny Asset Management LP
 Balyasny Asset Management LP Investment ManagersFinance BAM aims to deliver consistent, uncorrelated absolute returns in all market environments. The firm manages multi-strategy investment funds which maintain a concentrated private equity portfolio. Their investment advisory services reflect a blend of strategies including fundamental long/short equity, macro & rates, systematic trading and event & credit investing. BAM’s long/short equity and equity trading strategies include (but are not limited to) investments and trading in the following market sectors: Energy, Health Care, Financials, Industrials, Information Technology, Consumer Staples and Consumer Discretionary. | Finance |
Parkway Holdings Ltd.
 Parkway Holdings Ltd. Hospital/Nursing ManagementHealth Services Operates hospitals | Health Services |
Cornell University
 Cornell University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Agilus Diagnostics Ltd.
Agilus Diagnostics Ltd. Medical/Nursing ServicesHealth Services Provides diagnostic services | Health Services |
Albany Medical College
 Albany Medical College Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bearing Circle Capital LP | |
Globavir Biosciences, Inc.
Globavir Biosciences, Inc. Miscellaneous Commercial ServicesCommercial Services Engages in development of therapeutics and diagnostics for treatment of infectious diseases | Commercial Services |
BioXcel Corp.
BioXcel Corp. Data Processing ServicesTechnology Services Provides pharma data analytics solutions | Technology Services |
BioXcel Therapeutics, Inc.
 BioXcel Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops transformative medicines in neuroscience and immuno-oncology | Health Technology |
9 Meters Biopharma, Inc.
 9 Meters Biopharma, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals for people with rare digestive diseases and gastrointestinal conditions | Health Technology |
Unicycive Therapeutics, Inc.
 Unicycive Therapeutics, Inc. BiotechnologyHealth Technology Develops therapeutic drugs to treat kidney diseases | Health Technology |
Instil Bio, Inc.
 Instil Bio, Inc. BiotechnologyHealth Technology Develops tumour infiltrating lymphocytes for the treatment of cancer | Health Technology |
Invea Therapeutics, Inc.
Invea Therapeutics, Inc. BiotechnologyHealth Technology Operates as a biotechnology company developing small molecule oral therapeutics for immune-mediated inflammatory diseases, or IMIDs | Health Technology |
